T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphomas (T-LBL) are aggressive malignancies of thymocytes. The role of thymic microenvironmental cells and stromal factors in thymocyte malignant transformation and T-ALL development remains little explored. Here, using the TEL-JAK2 transgenic (TJ2-Tg) mouse model of T-ALL/LBL, which is driven by constitutive JAK/STAT signaling and characterized by the acquisition of Notch1 mutations, we sought to identify stromal cell alterations associated with thymic leukemogenesis. Immunofluorescence analyses showed that thymic lymphomas presented epithelial areas characterized by keratin (Krt) 5 and Krt8 expression, adjacently to epithelial-free areas negative for Krt expression. Both areas contained abundant laminin (extracellular matrix) and ER-TR7 + (fibroblasts) CD31 + (endothelial) and CD11c + (dendritic) cells. Besides Krt5, Krt-positive areas harbored medullary thymic epithelial cells (TECs) labeled by Ulex europaeus agglutinin-1. By performing flow cytometry and RNA sequencing analyses of thymic lymphomas, we observed an enrichment in medullary TEC markers in detriment of cortical TEC markers. To assess whether TECs are important for T-ALL/LBL development, we generated TJ2-Tg mice heterozygous for the FoxN1 transcription factor nude null mutation (Foxn1 +/nu ). Strikingly, in TJ2-Tg;Foxn1 +/nu compound mice, both emergence of malignant cells in preleukemic thymi and overt T-ALL onset were significantly delayed. Moreover, in transplantation assays, leukemic cell expansion within the thymus of recipient Foxn1 +/nu mice was reduced as compared with control littermates. Since thymopoesis is largely normal in Foxn1 +/nu mice, these results indicate that FoxN1 haploinsufficiency in TECs has a more profound impact in thymic leukemogenesis.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphomas (T-LBL) are aggressive thymocyte malignancies, as supported by similarities in the immunophenotypic, genotypic and transcriptomic profile of these leukemic cells and specific stages of intrathymic T-cell differentiation (1) (2) (3) . During intrathymic thymocyte differentiation, transformation events can lead to aberrant expression of oncogenic transcription factors that induce maturation arrest (4) . Genetic abnormalities in T-ALL, including chromosomal translocations, point mutations and deletions (4) , typically result in the activation of signaling pathways frequently involved in cancer, most notably the PTEN/ PI3K/AKT, Ras/MAPK and JAK/STAT pathways (5) . Furthermore, one of the most common genetic alterations in T-ALL and T-LBL are Notch1-activating point mutations, present in >60% of cases (4, 6) . The same signaling pathways that are activated by intrinsic oncogenic mutations can also be activated by extrinsic signals provided by stromal cells in organs where T-ALL cells thrive. For example, despite the frequent presence of Notch1 mutations, T-ALL cells were shown to respond to and be maintained in vitro by NOTCH ligands, such as Delta-like ligands 1 and 4 (7) (8) (9) .
Several extrinsic factors promoting T-ALL growth in vitro and in vivo were identified, including interleukin-7 (10-12), interleukin-18 (13), insulin-like growth factor (IGF)-1 (14) , ICAM-1 (15) and CXCL12 (16, 17) . However, it remained unclear to what extent T-ALL development depends on signals from its native thymic microenvironment. In this regard, pioneering thymectomy experiments in mouse models have since long hinted that the thymic microenvironment was essential for T-cell acute leukemia/lymphoma (18, 19) . Subsequent reports indicated that stromal signals are important for leukemia maintenance, as the physical contact with thymic microenvironmental cells was shown to improve survival of cocultured thymic-derived rodent primary leukemic T-cells (20, 21) . Furthermore, histological and immunophenotypical studies showed that the thymic stroma undergoes profound alterations throughout thymic leukemogenesis in mice (22) (23) (24) . Supportive of the role of the thymic microenvironment in human T-cell leukemogenesis, several T-ALL and T-LBL patients present thymic enlargement at diagnosis (3, 25, 26) . Moreover, patient cells were shown to expand in alymphoid fetal thymic organ cultures from NOD/SCID mouse without supplementation of exogenous factors (27) .
Thymopoiesis arises from incoming bone marrow progenitors that undergo T-cell differentiation upon stimulation by thymic microenvironmental molecular signals. T-cell progenitors become committed to the cell lineage at an immature phase characterized by the occurrence of genetic rearrangements of T-cell receptor (TCR) loci and identified by variable surface expression of CD25 and CD44 proteins and absence of CD4 and CD8 expression (double negative or DN stage). Cells undergoing successful TCR β chain rearrangement express first CD8 and become immature single-positive CD8 and then also CD4 and become so-called double-positive thymocytes. Depending on successful TCR α chain generation and negative and positive selection mediated by interactions with major histocompatibility complexes (MHC), thymocytes further differentiate into mature CD4 or CD8 single-positive T-cells or regulatory T-cells. Thymocyte development is achieved through a well-orchestrated bidirectional communication (so-called thymic cross talk) between stromal cells and maturing thymocytes. These interactions trigger molecular changes in the thymic stromal microenvironment that are essential for thymocyte migration, differentiation and selection of functional mature T-cells tolerant to self-antigens (28) . The thymic microenvironment is composed of epithelial, mesenchymal, endothelial and hematopoietic cells [B lymphocytes, dendritic cells (DCs) and macrophages]. Thymic epithelial cells (TECs) are essential for the architecture of the embryonic and postnatal thymus, as demonstrated by genetic inactivation of the transcription factor FoxN1, an essential master regulator of TEC differentiation (29, 30) . The spatial organization of the thymus into compartments is associated with functionally different TEC subpopulations that are involved in the generation of successive stages of thymocyte development (31) . Of note, cortical TECs (cTECs) are involved in T-cell lineage commitment and positive selection of thymocytes expressing functional TCR complexes, whereas medullary TECs (mTECs) are important for the generation of self-tolerant mature T-cells. This function is mediated through MHC-mediated presentation of tissue-restricted self-antigens, which are essential for the negative selection of autoreactive thymocytes and the generation of regulatory T-cells (32) .
The thymic molecular and cellular players involved in stromal support of thymocyte leukemogenesis have only recently begun to be explored. Our group has reported that stromal cell inactivation of the RelB transcription factor and the tumor necrosis factor receptor superfamily member lymphotoxin-β receptor, both components of the non-canonical NF-κB signaling pathway, delayed T-cell leukemia development in a transgenic mouse model expressing the TEL-JAK2 (also designated ETV6-JAK2) fusion protein in the lymphoid lineage (33, 34) . Recently, Triplett et al. (35) found in another T-ALL mouse model that IGF1R was highly expressed by malignant cells and that high IGF-1 secretion by tumor-associated thymic DCs favored leukemic cell survival. Together, these data suggest that thymic microenvironmental cells participate in the development of T-cell leukemia.
In the present study, we characterized the stromal cellular alterations in thymic leukemogenesis and found an increase in mTEC but not cTEC molecular markers. More importantly, we found that haploinsufficiency of the Foxn1 gene delayed thymic leukemogenesis.
Materials and methods

Mice
Mice were bred and maintained at the CBMR/UAlg and IBMC/i3S barrier animal facilities (HEPA filtration of incoming air, differential pressure and disinfection or sterilization of room equipment and supplies), under 12-h light/dark cycles and with autoclaved food (4RF25 diet; Mucedola, Settimo Milanese, Italy) and water ad libitum. Microorganism screening (Charles River, L'Arbresle, France and Idexx Bioresearch, Ludwigsburg, Germany) detected opportunistic pathogens (Helicobacter spp., Pasteurella pneumotropica and murine norovirus) in the CBMR/UAlg and IBMC/i3S experimental rooms. The animal facilities and project were approved by the i3S ethics committee and Portuguese authorities (Direção-Geral de Agricultura e Veterinária). All experimental procedures were performed in accordance with European (Directive 2010/63/UE) and Portuguese (Decreto-Lei nº113/2013) legislation. EμSRα-TEL-JAK2 (B6.Cg-Tg(Emu-ETV6/JAK2)71Ghy) APC  allophycocyanin  cTEC  cortical TEC  DCs  dendritic cells  IGF  insulin-like growth factor  KNAs  keratin-negative areas  Krt  keratin  MHC  major histocompatibility complexes  mTEC  medullary TEC  PBS  phosphate-buffered saline  PE  phycoerythrin  T-ALL  T-cell acute lymphoblastic leukemia  T-LBL  T-lymphoblastic lymphoma  TCR T-cell receptor TECs thymic epithelial cells UEA-1
Abbreviations
Ulex europaeus agglutinin-1 WT wild-type transgenic (TJ2-Tg) mice were described before (34, 36 
Flow cytometry detection of enzymatically dissociated thymic stromal cells
Thymic stromal cells were isolated by enzymatic digestion as described previously (37) . TECs were further enriched using a MACS-based CD45+ cell depletion kit (Miltenyi Biotec, Bergisch Gladbach, Germany Table 2 , available at Carcinogenesis Online) in 20 μl were analyzed on a CFX 96 Real-time PCR detection system (Bio-Rad). The mean fold change in expression of the gene of interest was calculated in relation to expression of a reference gene (Hprt) by the comparative C T method (2 −ΔΔC(T) method).
Genomic DNA extraction and Notch1 mutation detection
Genomic DNA was extracted from TJ2-Tg leukemic cells using the GeneJET Genomic DNA purification kit (Thermo Fisher Scientific), following the manufacturer's protocol. The exon 34 of Notch1 was PCR amplified as described previously (39) , and purified PCR products were Sanger sequenced at GenCore/i3S and CCMAR (Faro, Portugal).
Next generation sequencing
Thymic stromal cell-enriched fractions from WT (5 male) and TJ2-Tg (1 female and 2 male) mice were obtained as described above, and total RNA was extracted using the Direct-zol RNA Miniprep kit (Zymo Research). Next, mRNA was isolated using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs, Ipswich, MA), following the manufacturer's instructions. The WT and TJ2-Tg mRNA samples were pooled and purified using the RNeasy MinElute Cleanup kit (Qiagen) and further processed using the Ion Total RNA-Seq kit v2 (Thermo Fisher Scientific). Sequencing was performed on Ion Torrent PGM (Thermo Fisher Scientific) using Ion 316 Chip kits v2 (Thermo Fisher Scientific) for the WT and TJ2-Tg pooled samples. Both FastQC and Prinseq indicated high sequence quality except for a residual adapter sequence in a subpopulation of reads. The latter was removed by Cutadapt software. Additionally, reads were trimmed when the corresponding Phred score fell <25. Subsequently, reads were aligned to the full mouse genome (UCSC, version mm10) by the Torrent Mapping Alignment Program (TMAP). In total, 3 204 955 WT and 3 125 039 TJ2-Tg reads were mapped to the mouse genome. Gene expression levels were obtained by HTseq-count, and differential gene expression was assessed with Bioconductor package edgeR.
Statistical analysis
Graphs and statistical analyses were performed with GraphPad Prism software (La Jolla, CA). Statistical tests are indicated in the figure legends. Two-tailed t-tests were used to determine how significant were the differences between the means of two independent samples. Welch's correction was applied when variances were unequal, as determined by the F-test.
Results
TEL-JAK2 transgenic mouse thymic lymphomas present profound histological changes as compared with healthy thymi
Transgenic expression of the TEL-JAK2 fusion protein in the lymphoid cell lineage (driven by the EμSRα enhancer/promoter) results in T-cell leukemia and lymphoma, affecting the thymus, spleen, lymph nodes and other organs (36) . Signs of disease (labored breathing or abdominal or nodal enlargement) in TJ2-Tg mice manifest at variable ages, usually between 8 and 20 weeks.
No abnormalities in T-cell development are apparent in the initial weeks of life, but blind analysis of seemingly healthy 8-week-old TJ2-Tg mice revealed that in a subset of mice, leukemic cells (identified by aberrant CD8 and CD25 coexpression) could be detected only in the thymus or in higher numbers in this organ than in other body locations (34) . Further indicating that malignancy arises in the thymus, genetic blockade of T-cell development at the double-positive stage did not hamper leukemia/lymphoma development (40) . Thymic lymphomas from TJ2-Tg mice often become 10-20 times larger than age-matched control thymi and lose the typical thymic compartmentalization in cortex and medulla (36) . To characterize in more detail the thymic microenvironmental changes during TJ2-Tg-induced leukemogenesis, we assessed the spatial distribution of several thymic stromal cells in diseased mice. Immunofluorescence analysis of large thymic lymphomas from overtly ill mice with antibodies against the keratin (Krt) 5 and Krt8 epithelial cell markers revealed large cellular regions lacking both Krt5 and Krt8 labeling, here designated as Krt-negative areas (KNAs) (Supplementary Figure 1A As reported, fibroblast labeling by the ER-TR7 antibody was not restricted to any particular region of the WT thymus but was more abundant in the thymic capsule, trabeculae and lining of blood vessels (Figure 1 , panels d1 and d2) (42) . In TJ2-Tg thymic lymphomas, the pattern of ER-TR7 expression was similar in both Krt-positive and -negative areas, although a layer of ER-TR7 + cells marked the border between these two areas ( Figure 1 , panels d3 and d4, and Supplementary Figure 3A , available at Carcinogenesis Online). Laminin labeling was similar to ER-TR7 labeling, in that it was present throughout the tumor tissue, irrespective of Krt labeling, and marking the boundary between Krt-positive and -negative areas (Figure 1, panels e1-e4) . The CD31 marker, labeling endothelial cells, was also present throughout the thymic lymphoma tissue (Figure 1 , panels f1-f4). Double immunofluorescence analyses showed that all CD31
+ lymphoma blood vessels were surrounded by laminin (Supplementary Figure 3B , available at Carcinogenesis Online), which is normally a component of vascular basement membranes (43) .
Although F4/80 + macrophages were scattered in normal thymic tissue (Figure 1 , panels g1 and g2), these cells were also distributed throughout thymic lymphomas, albeit more abundantly in Krt-positive areas (Figure 1, panels g3 and g4) . Finally, we also analyzed the distribution pattern of the integrin-binding ICAM-1 adhesion molecule. As reported previously (44, 45) , ICAM-1 was detected both in the thymus cortex and medulla, although more prominently in the latter (Figure 1 , panels h1 and h2). In TJ2-Tg thymic lymphomas, ICAM-1 expression was more prevalent in areas of stronger Krt5 labeling (Figure 1 , panels h3 and h4), often colocalizing at the cellular level (Supplementary Figure 3C , available at Carcinogenesis Online).
The immunohistological data indicate that the composition of TECs is altered in thymic lymphomas, with a predominance for mTEC marker expression. To evaluate TEC alterations through another method, we performed gene expression analysis of whole thymic lymphomas. Quantitative PCR revealed a significant decrease in Krt5 and Krt8 transcripts within lymphomas as compared with normal whole thymi, confirming the notion that the proportion of TECs was reduced (Supplementary  Figure 4 , available at Carcinogenesis Online). Furthermore, the ratio of Krt5/Krt8 mRNA levels was significantly higher in lymphomas than in normal thymi (Supplementary Figure 4 , available at Carcinogenesis Online), thus supporting the notion that mTEC markers dominate over cTEC markers in those tumors.
Since the aforementioned results were based on analysis of large thymic lymphomas (from overtly ill TJ2-Tg mice), weighing from 500 to 1400 mg, we also assessed by immunofluorescence the extent of stromal cell alterations in smaller lymphomas, i.e. above the weight of a normal adult thymi (between 50 and 100 mg) but <400 mg (Figure 2A ). These analyses led to two main findings. First, Krt5 labeling was expanded in relation to Krt8 labeling, with concomitant loss of the normal corticomedullary compartmentalization ( Figure 2A, second row panels) . Second, the extension of KNAs, which contained abundant ER-TR7 + fibroblasts, increased with lymphoma size (Figure 2A , third row panels). Since an evident expansion of Krt5 + in relation to Krt8 + areas was recurrently detected in TJ2-Tg thymic lymphomas, we have also immunostained thymic lymphomas for the UEA-1 medullary marker, and this led to a similar staining pattern as that of Krt5 (Figure 2A , bottom panels). These results indicate that Krt5 + UEA-1 + TECs expand in detriment of Krt8 + TECs during lymphoma formation.
Flow cytometry detection of thymic lymphomaderived stromal cells
To further characterize the TEC subpopulations in TJ2-Tg thymic lymphomagenesis, we compared the representation of cTEC (defined as CD45 
Global gene expression analysis reveals alterations in thymic stromal cell composition early in leukemogenesis
To gain further insights into the nature of the stromal cell alterations in thymic leukemogenesis, we used an unbiased genome-wide transcriptomic approach. Because thymocytes represent the overwhelming majority of thymic cells and we aimed to obtain transcriptomic data from stromal populations, we depleted the former from thymic samples by mechanical Figure 1 . Characterization of the thymic stromal cellular alterations in advanced stage thymic lymphomas from TJ2-Tg mice. Double immunofluorescence staining of a WT thymus (panels numbered 1 and 2) and two representative TJ2-Tg thymic lymphomas (mouse nº341, panels numbered 3 and 4, except panels b3 and b4; mouse nº128, panels b3 and b4) out of at least three analyzed, with antibodies against the indicated markers. The higher magnification panels (numbered 2 and 4) depict a thymic region encompassing both medulla and cortex (panels a2-g2) and Krt-positive and -negative boundaries (panels a4-h4). For panels a1, b1, a3 and b3, DAPI staining (blue) is shown. Scale bars: 200 μm (panels numbered 1 and 3), 400 μm (panels numbered 2 and 4). When present, dashed-line rectangles represent the magnified area. disruption of thymic fragments, a procedure that mostly liberates hematopoietic cells. Since standard thymus enzymatic digestion protocols may lead to uneven depletion of specific stromal cell types (46,47), we extracted RNA from non-digested stromal cell-enriched thymic fractions (see Materials and methods section). This fractionation method maintained a diverse set of stromal cells (including TECs, DCs and mesenchymal cells) and led to enrichment of thymic stromal cell genes and depletion (but not exclusion) of thymocyte-specific genes (Supplementary Figure 5 , available at Carcinogenesis Online). We compared WT with TJ2-Tg (8-to 10-week old) mice with no external signs of disease but presenting incipient leukemogenesis, defined by normal-sized thymi (<100 mg) and the presence of low proportions (10-22%) of CD8 + CD25 + leukemic cells within the thymocyte population (data not shown). Pooled RNA samples were subjected to high-throughput sequencing, and bioinformatic analyses disclosed 640 differentially expressed genes, 199 upregulated in WT thymi (Supplementary  Table 3 , available at Carcinogenesis Online) and 441 upregulated in TJ2-Tg thymi (Supplementary Table 4 , available at Carcinogenesis Online). As expected from the crude stromal fractionation, several genes differentially expressed between WT and TJ2-Tg samples most probably derive from T-lineage cells (Ptcra, Rag1, Rag2, Dntt, Themis, etc.). Nevertheless, many upregulated or downregulated genes were well-characterized stromal cell markers (Ccl25, Vim, Lepr, S100a4, Zbtb46, Xcl1, etc.). To know whether the identified differentially expressed genes reflect an imbalanced representation of distinct thymic stromal cell proportions, we investigated whether those genes matched lineage-restricted genes expressed in particular thymic stromal cell subsets, as identified previously by Ki et al. (48) . Interestingly, of 116 cTEC-specific genes, 17 were upregulated in WT compared with TJ2-Tg thymi, whereas none was upregulated in TJ2-Tg compared with WT thymi ( Figure 2B and C, and Supplementary Table 5, available at Carcinogenesis Online). These findings confirmed that cTEC markers are downregulated during lymphomagenesis. In contrast, mTECspecific genes were not significantly enriched in either WT or TJ2-Tg samples. In addition, we observed that several genes specific of Sirpα + DCs were upregulated in TJ2-Tg but not WT thymi (Figure 2B and C and Supplementary Table 5, available at Carcinogenesis Online). These data indicate that thymic leukemogenesis in TJ2-Tg mice is accompanied by alterations in TEC subset proportions and an increase in DCs. 
Foxn1 haploinsufficiency delays the onset of TEL-JAK2-induced leukemia
To assess whether TECs play a role in thymic leukemogenesis, we generated TJ2-Tg mice lacking one Foxn1 allele, a gene shown to influence TEC development and maintenance in a dose-dependent manner (29 Figure 6A and B, available at Carcinogenesis Online), which are the main cellular targets for TJ2-Tg malignant transformation (40) . It was reported that Foxn1 +/nu mice younger than 5 weeks of age present lower thymic weight than WT controls (29, 49, 50) . Since TJ2-Tg leukemia arises during adulthood, i.e. between 6 and 20 weeks, we determined the thymic weight in older mice. Although 8-or 20-week-old Foxn1 +/nu mice presented slightly smaller thymi than Foxn1 +/+ littermates (1.1-to 1.3-fold difference) (Supplementary Figure 6C , available at Carcinogenesis Online), no statistically significant differences in thymic weight were found when considering females alone or older mice (7-9 months) of both sexes (Supplementary Figure 6C and D, available at Carcinogenesis Online). Strikingly, comparison of Foxn1 +/+ and Foxn1 +/nu TJ2-Tg mouse cohorts showed that the onset of leukemia was delayed in TJ2-Tg mice with Foxn1 haploinsufficiency ( Figure 4A ). Survival analysis of each sex separately revealed that Foxn1 haploinsufficiency delayed leukemia onset in both settings ( Figure 4B ). Despite the different survival rates of the two cohorts, no significant differences were observed regarding end-stage tumor load ( Figure 4C ). Moreover, overtly diseased TJ2-Tg;Foxn1 +/nu mice presented leukemic cells expressing characteristic markers (CD3, CD4, CD8, CD24 and CD25), and thymic lymphomas displayed KNAs and areas of overlapping Krt5 and Krt8 staining as control Foxn1 +/+ lymphomas (Supplementary Figure 7 , available at Carcinogenesis Online). Like in other T-ALL mouse models, TJ2-Tg leukemic cells were found to acquire activating frameshift mutations in the PEST domainencoding Notch1 exon 34 (>65% incidence) (Supplementary Table 6 , available at Carcinogenesis Online). Notch1 PEST domain heterozygous mutations, identified by the simultaneous detection of WT and mutated sequences (Supplementary Figure 8 , available at Carcinogenesis Online), occurred with similar frequency, in leukemic cells from both Foxn1 haploinsufficient and control TJ2-Tg mice (Table 1) . These mutations consisted of deletions and/or insertions, often affecting the previously reported exon 34 hotspots (codons 2361 and 2398/99) (39, 51, 52) and leading to premature stop codons and predicted loss of the C-terminal PEST domain (Table 1) . Together, these data indicate that FoxN1 haploinsufficiency delayed leukemogenesis without influencing the major disease characteristics.
To investigate whether thymic defects caused by Foxn1 haploinsufficiency impacted on the earliest detectable phases of leukemogenesis, we monitored the emergence of leukemic cells in young (8-week old) predisease TJ2-Tg mice through detection of CD8 + CD25
+ leukemic cells within total thymocytes ( Figure 4D ). At this age, leukemic cells can be detected in TJ2-Tg thymi without significant organ enlargement (34) . Indeed, thymic weight in the analyzed Foxn1 +/+ and Foxn1 +/nu TJ2-Tg mice was not significantly different, and it did not correlate with the percentage of detected CD8 + CD25
+ leukemic cells ( Figure 4E ). However, thymi from TJ2-Tg;Foxn1 +/nu mice displayed a significantly lower percentage of CD8 + CD25 + cells than TJ2-Tg;Foxn1 +/+ thymi (7.8-fold difference; Figure 4F ). Since TJ2-Tg leukemic cells are generated intrathymically (34), CD8 + CD25 + cells were barely detectable in the blood, bone marrow and spleen of mice of both Foxn1 genotypes ( Figure 4F and data not shown). These findings indicate that leukemic cell emergence in the thymus is delayed when Foxn1 gene dosage is reduced in TEC. Although Foxn1 haploinsufficiency leads to a mild decrease in thymic size, which could contribute to the observed delayed leukemogenesis, the above-presented data suggest that reduction in FoxN1 expression levels in TECs has a more marked impact on leukemogenesis than on thymocyte generation and differentiation.
The Foxn1-dependent thymic microenvironment facilitates leukemic cell expansion
To determine the role of the Foxn1-dependent microenvironment in leukemia maintenance, leukemic cells were collected from diseased TJ2-Tg mice and infused into non-conditioned syngeneic Foxn1 +/nu and Foxn1 +/+ littermate controls ( Figure 5A ). When manifesting signs of disease, recipient mice were killed for macroscopic and flow cytometry analyses. Although the spleen and liver were the most invaded organs, thymi from all recipient mice became infiltrated by CD8 + CD25
+ leukemic cells ( Figure 5B ). Two independent experiments using either male or female recipients were performed, and each revealed a trend toward lower tumor load in Foxn1 +/nu thymi ( Figure 5C ). Following data normalization and pooling, we found that Foxn1 +/nu mice displayed statistically significant lower thymic weight than Foxn1 +/+ littermates ( Figure 5D ). In contrast, the relative splenic and hepatic tumor load was not influenced by Foxn1 genotype ( Figure 5D ). These results thus indicate that Foxn1 expression in TECs promotes leukemic cell expansion in the thymus.
Discussion
The malignant transformation of mouse or human thymocytes is triggered by the deregulation of key cellular mechanisms due to both cell-intrinsic genetic alterations and microenvironmental stimulation (53, 54) . Here, using a mouse model of JAK kinase-driven and Notch1-mutated T-ALL, we identified several microenvironmental cellular alterations associated with thymic lymphoma development and progression. These included shifts in expression of TEC markers, with loss of cortical and increase of medullary epithelial cell markers, together with increased proportions of fibroblasts, DCs and endothelial cells. Highlighting a role for TECs, we found that reducing the genetic dosage of FoxN1, an essential TEC transcription factor in TEC differentiation, delayed thymic leukemogenesis.
Diseased TJ2-Tg mice present large thymic lymphomas with loss of corticomedullary demarcation and frequent disruption of the thymic capsule (33, 36) . By performing immunohistological analyses against thymic Krt proteins, we observed that TJ2-Tg mouse thymic lymphomas developed conspicuous areas without Krt expression, which were more extensive in larger lymphomas. Similar observations were reported in thymic lymphomas from other mouse models (22, 35) . In TJ2-Tg mice, KNAs included fibroblasts and laminin-containing extracellular matrix, suggesting that leukemic cells first invade the capsular connective tissue before expanding outwardly, thus generating lymphomatous KNAs. By studying spontaneous thymic lymphomas of different sizes, we found that the normal corticomedullary demarcation was lost. This phenomenon was accompanied by a strong reduction in cortical (Krt8-positive, Krt5-negative) areas, which is in agreement with earlier reports of cortical atrophy and medullary expansion at preleukemic stages of viralinduced murine thymic lymphoma (23, 24, (55) (56) (57) . Our data thus support the concept that upon emergence of leukemic cells in the thymus, these disseminate throughout all thymic compartments, impacting on TEC differentiation and/or distribution, before invading the thymic capsule and undergoing further expansion.
FoxN1 is a pivotal transcription factor for thymus and skin epithelial cell differentiation in rodents and humans (58) . However, its role in cancer is less understood. Previous evidence indicated that FoxN1 suppresses the transition from benign to malignant keratinocyte lesions (59) . Another report supporting a tumor-suppressive role for Foxn1 showed that its haploinsufficiency accelerated thymic leukemogenesis in the endogenous retrovirus-expressing AKR murine strain (60) . In contrast with these data, we found that loss of a single Foxn1 allele hindered both the onset of spontaneous TEL-JAK2-induced leukemia/ lymphoma and the thymic expansion of leukemic cells in recipient mice. Since leukemogenesis in TJ2-Tg mice is initiated in the thymus (34, 40) and TECs are the only thymic cells expressing Foxn1, we conclude that the delayed leukemogenesis in heterozygotes is caused by FoxN1-mediated defects in TECs. Despite the observed delay in leukemia onset, all TJ2-Tg;Foxn1 +/nu mice succumbed to disease with similar pathological and molecular features as Foxn1 +/+ controls. These findings suggest that TJ2-Tg leukemogenesis is not profoundly altered by Foxn1 haploinsufficiency but that it takes longer to develop, at initiation and/or progression. The finding that preleukemic TJ2-Tg;Foxn1 + thymic cells than TJ2-Tg;Foxn1 +/+ mice suggests that Foxn1 haploinsufficiency in TECs impacts disease development very early on.
Foxn1 haploinsufficiency was shown to cause a moderate reduction in thymic weight of mice under 5 weeks of different outbred and inbred strains (29, 49, 50) . Young adult Foxn1 +/nu mice (8 and 20 weeks of age) displayed a mild reduction in thymic weight, which was less evident considering females alone or older mice, but no defects in Foxn1 +/nu thymocyte maturation were apparent. Further supporting the notion that delayed leukemogenesis caused by Foxn1 haploinsufficiency is not due to a mere decrease in thymocyte cellularity, the decrease in adult thymic weight at 8 weeks of age caused by loss of one Foxn1 allele was much less pronounced (1.3-fold) relatively to the delay in both emergence of thymic leukemic cells at 8 weeks (7.8-fold) and leukemia-related TJ2-Tg mouse death (2.2-fold higher mortality rate at 20 weeks of age). Although a putative role for reduced thymocyte cellularity cannot be formally excluded, our data indicate that the delayed thymic leukemogenesis caused by Foxn1 haploinsufficiency results from an as yet unidentified cellular mechanism acting specifically on leukemic cell propagation but not on thymocyte development.
Although the FoxN1-mediated mechanism fostering leukemogenesis remains unclear, it is possible that leukemic cell development is more sensitive than thymocyte development to changes in expression of specific FoxN1 target genes. In this line, we observed that Foxn1 haploinsufficiency was associated with a mild reduction in Ccl25 thymic expression (data not shown), a well-established FoxN1 target gene (61) and a potential T-ALL growth factor (62) . Future studies should address whether this or other FoxN1 target genes (e.g. Dll4 and Cxcl12) play direct roles in thymic leukemogenesis. Alternatively, FoxN1 could impinge on leukemogenesis indirectly through changes in functional properties of TECs or other thymic microenvironmental cells. Since thymic leukemogenesis is accompanied by a disorganization in TEC marker expression, it is possible that Foxn1 +/nu -associated TEC differentiation defects underlie the delayed leukemia onset in TJ2-Tg;Foxn1 +/nu mice. In addition, TECs were shown to regulate both thymic vascularization (63, 64) and thymic DC development, differentiation and recruitment (65) (66) (67) . Whether Foxn1 haploinsufficiency in TECs is linked to vascular or DC defects warrants further investigation.
It was shown previously that RelB and lymphotoxin-β receptor proteins, both expressed in mTEC and other thymic stromal cells, contribute to leukemogenesis (33, 34) . Additionally, these proteins are essential for thymic medulla development and maintenance, as shown by the impaired medullary compartment of the respective knock-out mice (68, 69) . The notion that RelB, lymphotoxin-β receptor and FoxN1 promote leukemogenesis and that all are expressed in mTECs suggest that these or other medullary cell types are involved in thymic leukemogenesis.
Using a panel of thymic cell markers, we detected major organizational alterations involving several thymic stromal cell types in smaller and larger TJ2-induced lymphomas. Most notably, we observed increased expression of CD31 and ER-TR7, markers for endothelial cells and thymic fibroblasts, respectively, suggesting that angiogenesis, fibroblast proliferation and accrued extracellular matrix deposition, which are often associated with cancer (70), may favor thymic lymphomagenesis, especially at the most advanced stages. We have also found expression of markers for macrophages (F4/80) and DCs (CD11c and DEC205) in lymphomas. Macrophages have been identified in mouse thymic lymphomas (56, 71) , and recent studies indicate that lymphoma-associated macrophages stimulate T-ALL proliferation in vitro (72) . Thus, the potential involvement of tumorassociated macrophages in T-cell leukemogenesis merits further investigation. DCs are usually associated with an antitumoral role via their function in adaptive immunity as tumor antigen-presenting cells (73) . However, it was recently shown that DCs favored survival or proliferation of B-and T-leukemic cells (35, 74) . More specifically, Triplett et al. (35) . reported that thymic lymphoma-derived DCs (most notably Sirpα-positive DCs) promoted leukemic T-cell survival through IGF-1 and PDGF (platelet-derived growth factor) secretion. An increased proportion of DCs and increased expression of Sirpα + DC genes were found in the stroma of TJ2-Tg thymic lymphomas, so studies determining whether DCs are involved in TJ2 leukemogenesis are warranted.
Together, our findings demonstrate that the thymic microenvironment in general and TECs specifically are crucial for the malignant transformation of thymocytes. The identification of the key molecular signals produced by stromal cells will not only shed further light on the mechanisms underlying T-cell leukemogenesis but may also be instrumental for the design of therapies targeting these malignancies.
Supplementary material
Supplementary data can be found at Carcinogenesis online. 
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